TL;DR
Roche’s anti-TIGIT drug tiragolumab did not meet its primary endpoint in a Phase 3 trial for non-small-cell lung cancer, leading to a reevaluation of TIGIT-targeted therapies. Multiple companies had invested heavily in this approach, but the setback raises doubts about TIGIT’s potential as a cancer treatment.
Roche announced in May 2022 that its experimental anti-TIGIT drug, tiragolumab, failed to improve overall survival in a Phase 3 trial for metastatic non-small-cell lung cancer, marking a significant setback for the promising class of cancer immunotherapies targeting TIGIT.
The Phase 3 SKYSCAPER trial involved approximately 5,000 patients across multiple cancer subtypes and was designed to evaluate tiragolumab combined with standard chemotherapy. Despite encouraging earlier results and a breakthrough designation from the FDA in January 2021, the trial did not meet its primary endpoint of extending overall survival. Roche had invested heavily in the TIGIT program, running up to a dozen parallel trials under the SKYSCAPER initiative, which cost billions. The failure has prompted a reassessment among other pharmaceutical companies developing similar drugs, including Merck, BMS, BeiGene, Arcus, and GSK, all of whom had active TIGIT programs.
Roche’s initial phase 2 trial in 2020 showed promising response rates, leading to rapid advancement into phase 3. The company had hoped tiragolumab would outperform existing immunotherapies like Keytruda, which has generated billions in revenue. However, the late-stage results have cast doubt on the efficacy of TIGIT as a standalone or combination therapy for lung cancer and potentially other indications.
Why It Matters
This failure signifies a major shift in the landscape of cancer immunotherapy development. Despite early optimism, the setback suggests that TIGIT may not be the breakthrough many had anticipated, potentially redirecting billions of dollars in investment and prompting a reevaluation of immune checkpoint strategies. For patients and clinicians, it underscores the ongoing challenges in translating promising biological targets into effective treatments.
cancer immunotherapy research books
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Background
TIGIT emerged as a promising immune checkpoint target after decades of research into cancer immunotherapy. The success of PD-1 inhibitors like Keytruda in the mid-2010s spurred intense interest in finding additional targets. Roche’s 2014 publication highlighted TIGIT’s role in immune regulation, leading to rapid development of anti-TIGIT drugs. The initial phase 2 results in 2020 generated optimism, prompting multiple companies to invest heavily. Roche’s SKYSCAPER program, one of the largest in immuno-oncology, aimed to establish TIGIT as a major therapeutic class. The recent failure in phase 3 marks the first major setback after years of high expectations.
“The phase 3 trial did not meet its primary endpoint, and we are carefully analyzing the data to determine next steps.”
— Roche spokesperson
“This setback raises serious questions about TIGIT’s viability as a cancer target and may slow or halt further development in this class.”
— Industry analyst
immune checkpoint inhibitor guide
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What Remains Unclear
It is not yet clear whether other TIGIT drugs in development will face similar setbacks or if specific indications might still benefit from this approach. The full data from Roche’s trial has not been publicly released, and further analysis is needed to understand the underlying reasons for the failure.
cancer treatment educational materials
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What’s Next
Roche and other companies will likely reexamine their TIGIT programs, potentially halting ongoing trials or redirecting resources. Future research may focus on understanding why the approach failed and exploring alternative strategies in immune checkpoint therapy. Additional data releases from Roche are expected in the coming months to clarify the trial outcomes.
oncology patient support products
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is TIGIT and why was it considered promising?
TIGIT is a protein that acts as an immune checkpoint, potentially suppressing immune responses against tumors. Blocking it was thought to unleash immune cells to attack cancer more effectively, similar to other successful immunotherapies like PD-1 inhibitors.
Why did the tiragolumab trial fail?
The specific reasons are not yet publicly confirmed, but the failure suggests that blocking TIGIT may not provide the expected clinical benefit in the tested patient populations or that the biological hypothesis needs reevaluation.
Does this mean TIGIT drugs are dead?
Not necessarily. While this setback is significant, other companies have ongoing TIGIT programs. Further research and data are needed to determine if any TIGIT-targeted therapies can still succeed.
What impact does this have on cancer immunotherapy development?
This failure may slow investment and development in TIGIT-based therapies and shift focus toward other immune targets. It also underscores the difficulty of translating promising biological targets into effective treatments.
Source: Hacker News
